BTG CASE STUDIES > ONCOLOGY

Indication Prioritization

The VP of Global Marketing at a F200 pharma company was reviewing a promising drug about to enter Phase II of R&D. The company’s lean team had already completed a broad indication assessment, but they needed help preparing a more detailed opportunity assessment that leveraged…

READ MORE


Accelerating an Oncology Drug Launch

A F300 pharma company was preparing to launch a new oncology drug. But its understaffed pricing and market access group was struggling to create global access plans and strategies. Expecting accelerated regulatory approvals in the US and Europe, the company’s Director of Global Pricing turned…

READ MORE


Oncology Market Access Support

The lean market access group at a global pharma company was preparing to launch a recently acquired pipeline oncology asset. Yet they were struggling to coordinate US payer marketing activities. Looking for additional expertise in oncology market access, they turned to Business Talent Group. Our…

READ MORE


Oncology Assessment for Biosimilar In-licensing

The head of marketing for a biopharma company’s biosimilars business unit was struggling to size two oncology in-licensing opportunities in the U.S. and Europe. Looking for an informed assessment—and a broader picture of biosimilar developments in the oncology market—she turned to Business Talent Group. Our…

READ MORE


Send this to a friend